Clinical Trial Update: A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Fovista (E10030) plus Lucentis versus Lucentis alone in age-related macular degeneration was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Fovista (E10030)
• Lucentis (ranibizumab)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Age-Related Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2018-08-15